LIFECORE BIOMEDICAL, INC. Contract with Customer, Asset, Reclassified to Receivable
LIFECORE BIOMEDICAL, INC. (LFCR) reported Contract with Customer, Asset, Reclassified to Receivable of $6.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:ContractWithCustomerAssetReclassifiedToReceivable · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2026-06-30 was $1.28M.
- LIFECORE BIOMEDICAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2026-03-31 was $5.07M.
- LIFECORE BIOMEDICAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2025-09-30 was $4.96M.
- LIFECORE BIOMEDICAL, INC. contract with customer, asset, reclassified to receivable for the quarter ending 2025-05-25 was $146.00K.
- LIFECORE BIOMEDICAL, INC. contract with customer, asset, reclassified to receivable for fiscal 2025 was $4.07M.
| Period end | Contract with Customer, Asset, Reclassified to Receivable 3 month | Contract with Customer, Asset, Reclassified to Receivable 6 month | Contract with Customer, Asset, Reclassified to Receivable 7 month | Contract with Customer, Asset, Reclassified to Receivable 9 month | Contract with Customer, Asset, Reclassified to Receivable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.34M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $5.07M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $6.33M 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | $4.96M 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | $146.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $4.07M 10-KT · filed 2026-03-16 | |||
| 2025-02-23 | $3.92M 10-Q · filed 2025-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |